×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VNRX – volitionrx limited (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VNRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/25
08:39 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
2/25
08:10 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
2/10
08:07 am
vnrx
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
High
Report
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
2/9
05:20 pm
vnrx
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Low
Report
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
2/4
08:45 am
vnrx
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Low
Report
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
1/30
08:50 am
vnrx
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
Medium
Report
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
1/27
08:00 am
vnrx
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Low
Report
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
1/21
08:00 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
High
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Plummer Nicholas
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Plummer Nicholas
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Batchelor Ann-Louise
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Batchelor Ann-Louise
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Rubin Ethel
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Rubin Ethel
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Reynolds Cameron John
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Reynolds Cameron John
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Rootsaert Rodney Gerard
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Rootsaert Rodney Gerard
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Forterre Gael
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Forterre Gael
2/27
04:34 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Hughes Terig
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Hughes Terig
2/27
04:33 pm
vnrx
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Kway Jasmine
Low
Report
Form 4 VOLITIONRX LTD For: Feb 26 Filed by: Kway Jasmine
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/17
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
10.1%
2/7 Form S-3 VOLITIONRX LTD 9.4%
11/7 VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update 8.6%
10/18 Form 4 VOLITIONRX LTD For: Oct 01 Filed by: Cotterford Co Ltd 6.4%
7/10 VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding 6.3%
8/16 Form 4 VOLITIONRX LTD For: Aug 15 Filed by: Faulkes Martin Charles 5.5%
3/22 VolitionRx (VNRX) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
10/18 Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas 4.6%
4/1 Form PRE 14A VOLITIONRX LTD For: Apr 01 4.2%
11/12 Form 10-Q VOLITIONRX LTD For: Sep 30 4.1%
2/7 Form S-3 VOLITIONRX LTD 9.4%
11/7 VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update 8.6%
10/18 Form 4 VOLITIONRX LTD For: Oct 01 Filed by: Cotterford Co Ltd 6.4%
7/10 VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding 6.3%
8/16 Form 4 VOLITIONRX LTD For: Aug 15 Filed by: Faulkes Martin Charles 5.5%
3/22 VolitionRx (VNRX) Investor Presentation - Slideshow [Seeking Alpha] 5.4%
10/18 Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas 4.6%
4/1 Form PRE 14A VOLITIONRX LTD For: Apr 01 4.2%
11/12 Form 10-Q VOLITIONRX LTD For: Sep 30 4.1%
TOP News Decliners
12/5
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
-13.4%
2/21 VolitionRx Limited 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] -10.5%
4/23 Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies -10.2%
2/27 Form 4 VOLITIONRX LTD For: Feb 26 Filed by: TERRELL JASON BRADLEY MD -9.8%
3/10 VolitionRx Limited Releases Annual Corporate Brochure and Video -7.2%
7/24 Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock -6.7%
4/29 Form DEF 14A VOLITIONRX LTD For: Apr 29 -5.3%
8/1 Form SC 13D VOLITIONRX LTD Filed by: Cotterford Co Ltd -3.7%
5/8 VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update -3.2%
8/8 Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer -3.0%
2/21 VolitionRx Limited 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] -10.5%
4/23 Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies -10.2%
2/27 Form 4 VOLITIONRX LTD For: Feb 26 Filed by: TERRELL JASON BRADLEY MD -9.8%
3/10 VolitionRx Limited Releases Annual Corporate Brochure and Video -7.2%
7/24 Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock -6.7%
4/29 Form DEF 14A VOLITIONRX LTD For: Apr 29 -5.3%
8/1 Form SC 13D VOLITIONRX LTD Filed by: Cotterford Co Ltd -3.7%
5/8 VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update -3.2%
8/8 Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: